Copaxone Continues Cleaning Tysabri’s Clock in US Market
[Updated for 2Q10 Tysabri sales.]
The US market is the one of consequence for MNTA investors insofar as this is where MNTA and partner NVS have submitted an application to market generic Copaxone. Below are Tysabri and Copaxone US sales for the past eight quarters with the recent year-over-year and quarter-over- quarter growth rates. Copaxone is outselling Tysabri in the US by about 3.5:1, while both drugs have YoY growth rates in the teens. Teva reports 2Q10 Copaxone sales on July 27.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.